Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Syvälahti E[au]:

Dopamine D1 receptor antagonism in schizophrenia: is there reduced risk of extrapyramidal side-effects? Hietala J et al. Trends Pharmacol Sci. (1990)

Biological aspects of depression. Syvälahti EK et al. Acta Psychiatr Scand Suppl. (1994)

Monoaminergic mechanisms in affective disorders. Syvälahti E et al. Med Biol. (1987)

Search results

Items: 1 to 50 of 156

1.

The effects of lorazepam on extrastriatal dopamine D(2/3)-receptors-A double-blind randomized placebo-controlled PET study.

Vilkman H, Kajander J, Aalto S, Vahlberg T, Någren K, Allonen T, Syvälahti E, Hietala J.

Psychiatry Res. 2009 Nov 30;174(2):130-7. doi: 10.1016/j.pscychresns.2009.04.006.

PMID:
19846281
2.

[Update on current care guidelines. Depression, current care guideline].

Isometsä E, Jousilahti P, Lindfors O, Luutonen S, Marttunen M, Pirkola S, Salminen JK, Kinnunen E, Pasternack I, Syvälahti E, Vuorilehto M.

Duodecim. 2009;125(16):1755-6. Finnish.

PMID:
19839194
3.

Laboratoriotutkimukset psykoosien ja mielialahäiriöiden lääkehoidon aikana.

Penttilä J, Appel H, Rintahaka P, Heikkinen R, Syvälahti E.

Duodecim. 2007;123(7):812-8. Finnish. No abstract available.

PMID:
17612114
4.

Quality of life and functioning ability in subjects vulnerable to psychosis.

Svirskis T, Korkeila J, Heinimaa M, Huttunen J, Ilonen T, Ristkari T, Hietala J, Syvälahti E, McGlashan T, Vahlberg T, Salokangas RK.

Compr Psychiatry. 2007 Mar-Apr;48(2):155-60. Epub 2007 Jan 4.

PMID:
17292706
5.

Psyykenläkehoito nuorisopsykiatriassa.

Penttilä J, Moilanen K, Rintahaka P, Syvälahti E.

Duodecim. 2006;122(20):2475-82. Finnish. No abstract available.

PMID:
17233353
6.

Predicting medication-free treatment response in acute psychosis: cross-validation from the Finnish Need-Adapted Project.

Bola JR, Lehtinen K, Aaltonen J, Räkköläinen V, Syvälahti E, Lehtinen V.

J Nerv Ment Dis. 2006 Oct;194(10):732-9.

PMID:
17041284
7.

Combined treatment with citalopram and buspirone: effects on serotonin 5-HT2A and 5-HT2C receptors in the rat brain.

Syvälahti E, Penttilä J, Majasuo H, Pälvimäki EP, Laakso A, Hietala J.

Pharmacopsychiatry. 2006 Jan;39(1):1-8.

PMID:
16453246
8.

[Care and treatment of insomnia].

Syvälahti E.

Duodecim. 2005;121(18):1950-1. Review. Finnish. No abstract available.

PMID:
16300308
9.

Measurement of anticholinergic effects of psychotropic drugs in humans.

Penttilä J, Scheinin H, Syvälahti E.

Pharmacopsychiatry. 2005 Sep;38(5):187-93. Review.

PMID:
16189744
10.

Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man.

Aalto S, Ihalainen J, Hirvonen J, Kajander J, Scheinin H, Tanila H, Någren K, Vilkman H, Gustafsson LL, Syvälahti E, Hietala J.

Psychopharmacology (Berl). 2005 Nov;182(3):375-83. Epub 2005 Oct 19.

PMID:
16001106
11.

The A1 allele of the human D2 dopamine receptor gene is associated with increased activity of striatal L-amino acid decarboxylase in healthy subjects.

Laakso A, Pohjalainen T, Bergman J, Kajander J, Haaparanta M, Solin O, Syvälahti E, Hietala J.

Pharmacogenet Genomics. 2005 Jun;15(6):387-91.

PMID:
15900211
12.

Serotonin 5-HT2C receptor-mediated phosphoinositide hydrolysis in rat choroid plexus after fluoxetine and citalopram treatments.

Pälvimäki EP, Majasuo H, Syvälahti E, Hietala J.

Pharmacol Res. 2005 May;51(5):419-25.

PMID:
15749456
13.

Effects of fluoxetine on dopamine D2 receptors in the human brain: a positron emission tomography study with [11C]raclopride.

Penttilä J, Kajander J, Aalto S, Hirvonen J, Någren K, Ilonen T, Syvälahti E, Hietala J.

Int J Neuropsychopharmacol. 2004 Dec;7(4):431-9. Epub 2004 Jul 26.

PMID:
15315717
14.

[Future directions for drug treatment of drug-resistant depression].

Isometsä E, Syvälahti E.

Duodecim. 2004;120(7):821-30. Review. Finnish. No abstract available.

PMID:
15154302
15.

The amygdala and schizophrenia: a volumetric magnetic resonance imaging study in first-episode, neuroleptic-naive patients.

Joyal CC, Laakso MP, Tiihonen J, Syvälahti E, Vilkman H, Laakso A, Alakare B, Räkköläinen V, Salokangas RK, Hietala J.

Biol Psychiatry. 2003 Dec 1;54(11):1302-4.

PMID:
14643099
16.

Regional brain morphology and duration of illness in never-medicated first-episode patients with schizophrenia.

Hietala J, Cannon TD, van Erp TG, Syvälahti E, Vilkman H, Laakso A, Vahlberg T, Alakare B, Räkköläinen V, Salokangas RK.

Schizophr Res. 2003 Nov 1;64(1):79-81. No abstract available.

PMID:
14511804
17.

Ethanol consumption and DRD2 gene TaqI a polymorphism among socially drinking males.

Hallikainen T, Hietala J, Kauhanen J, Pohjalainen T, Syvälahti E, Salonen JT, Tiihonen J.

Am J Med Genet A. 2003 Jun 1;119A(2):152-5.

PMID:
12749054
18.

Personality traits and striatal dopamine synthesis capacity in healthy subjects.

Laakso A, Wallius E, Kajander J, Bergman J, Eskola O, Solin O, Ilonen T, Salokangas RK, Syvälahti E, Hietala J.

Am J Psychiatry. 2003 May;160(5):904-10.

PMID:
12727694
19.

Ketamine does not decrease striatal dopamine D2 receptor binding in man.

Aalto S, Hirvonen J, Kajander J, Scheinin H, Någren K, Vilkman H, Gustafsson L, Syvälahti E, Hietala J.

Psychopharmacology (Berl). 2002 Dec;164(4):401-6. Epub 2002 Oct 12.

PMID:
12457270
20.

Sex differences in striatal presynaptic dopamine synthesis capacity in healthy subjects.

Laakso A, Vilkman H, Bergman J, Haaparanta M, Solin O, Syvälahti E, Salokangas RK, Hietala J.

Biol Psychiatry. 2002 Oct 1;52(7):759-63.

PMID:
12372667
21.

Structural magnetic resonance imaging in patients with first-episode schizophrenia, psychotic and severe non-psychotic depression and healthy controls. Results of the schizophrenia and affective psychoses (SAP) project.

Salokangas RK, Cannon T, Van Erp T, Ilonen T, Taiminen T, Karlsson H, Lauerma H, Leinonen KM, Wallenius E, Kaljonen A, Syvälahti E, Vilkman H, Alanen A, Hietala J.

Br J Psychiatry Suppl. 2002 Sep;43:s58-65.

PMID:
12271802
22.

A volumetric MRI study of the entorhinal cortex in first episode neuroleptic-naive schizophrenia.

Joyal CC, Laakso MP, Tiihonen J, Syvälahti E, Vilkman H, Laakso A, Alakare B, Räkköläinen V, Salokangas RK, Hietala J.

Biol Psychiatry. 2002 Jun 15;51(12):1005-7.

PMID:
12062885
23.

Analysis of monoamine oxidase A (MAOA) promoter polymorphism in Finnish male alcoholics.

Saito T, Lachman HM, Diaz L, Hallikainen T, Kauhanen J, Salonen JT, Ryynänen OP, Karvonen MK, Syvälahti E, Pohjalainen T, Hietala J, Tiihonen J.

Psychiatry Res. 2002 Mar 15;109(2):113-9.

PMID:
11927135
24.

Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia.

Laakso A, Bergman J, Haaparanta M, Vilkman H, Solin O, Syvälahti E, Hietala J.

Schizophr Res. 2001 Oct 1;52(1-2):115-20.

PMID:
11595398
25.

Sertindole is a serotonin 5-HT2c inverse agonist and decreases agonist but not antagonist binding to 5-HT2c receptors after chronic treatment.

Hietala J, Kuonnamäki M, Pälvimäki EP, Laakso A, Majasuo H, Syvälahti E.

Psychopharmacology (Berl). 2001 Sep;157(2):180-7.

PMID:
11594443
26.

[The use of imaging techniques in drug research].

Syvälahti E, Hietala J.

Duodecim. 1998;114(10):1019-26. Review. Finnish. No abstract available.

PMID:
11524776
27.
28.

A morphometric MRI study of the hippocampus in first-episode, neuroleptic-naïve schizophrenia.

Laakso MP, Tiihonen J, Syvälahti E, Vilkman H, Laakso A, Alakare B, Räkköläinen V, Salokangas RK, Koivisto E, Hietala J.

Schizophr Res. 2001 May 30;50(1-2):3-7.

PMID:
11378309
29.

The effects of amitriptyline, citalopram and reboxetine on autonomic nervous system. A randomised placebo-controlled study on healthy volunteers.

Penttilä J, Syvälahti E, Hinkka S, Kuusela T, Scheinin H.

Psychopharmacology (Berl). 2001 Apr;154(4):343-9.

PMID:
11349386
30.

Differential effects of fluoxetine and citalopram treatments on serotonin 5-HT(2C) receptor occupancy in rat brain.

Pälvimäki EP, Kuoppamäki M, Syvälahti E, Hietala J.

Int J Neuropsychopharmacol. 1999 Jun;2(2):95-99.

PMID:
11281975
31.

Measurement of extrastriatal D2-like receptor binding with [11C]FLB 457--a test-retest analysis.

Vilkman H, Kajander J, Någren K, Oikonen V, Syvälahti E, Hietala J.

Eur J Nucl Med. 2000 Nov;27(11):1666-73.

PMID:
11105823
32.

Two-year outcome in first-episode psychosis treated according to an integrated model. Is immediate neuroleptisation always needed?

Lehtinen V, Aaltonen J, Koffert T, Räkköläinen V, Syvälahti E.

Eur Psychiatry. 2000 Aug;15(5):312-20.

PMID:
10954876
33.

Lack of association between the functional variant of the catechol-o-methyltransferase (COMT) gene and early-onset alcoholism associated with severe antisocial behavior.

Hallikainen T, Lachman H, Saito T, Volavka J, Kauhanen J, Salonen JT, Ryynänen OP, Koulu M, Karvonen MK, Pohjalainen T, Syvälahti E, Hietala J, Tiihonen J.

Am J Med Genet. 2000 Jun 12;96(3):348-52.

PMID:
10898913
34.

Striatal D(2) dopamine receptor density and psychotic symptoms in schizophrenia: a longitudinal study.

Syvälahti EK, Räkköläinen V, Aaltonen J, Lehtinen V, Hietala J.

Schizophr Res. 2000 Jun 16;43(2-3):159-61. No abstract available.

PMID:
10858634
35.

The dopamine D2 receptor 5'-flanking variant, -141C Ins/Del, is not associated with reduced dopamine D2 receptor density in vivo.

Pohjalainen T, Någren K, Syvälahti EK, Hietala J.

Pharmacogenetics. 1999 Aug;9(4):505-9.

PMID:
10780270
36.

High levels of dopamine activity in the basal ganglia of cigarette smokers.

Salokangas RK, Vilkman H, Ilonen T, Taiminen T, Bergman J, Haaparanta M, Solin O, Alanen A, Syvälahti E, Hietala J.

Am J Psychiatry. 2000 Apr;157(4):632-4.

PMID:
10739427
37.

Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography.

Laakso A, Vilkman H, Alakare B, Haaparanta M, Bergman J, Solin O, Peurasaari J, Räkköläinen V, Syvälahti E, Hietala J.

Am J Psychiatry. 2000 Feb;157(2):269-71.

PMID:
10671399
38.

Association between low activity serotonin transporter promoter genotype and early onset alcoholism with habitual impulsive violent behavior.

Hallikainen T, Saito T, Lachman HM, Volavka J, Pohjalainen T, Ryynänen OP, Kauhanen J, Syvälahti E, Hietala J, Tiihonen J.

Mol Psychiatry. 1999 Jul;4(4):385-8.

39.

Brain 5-HT2A receptor occupancy of deramciclane in humans after a single oral administration--a positron emission tomography study.

Kanerva H, Vilkman H, Någren K, Kilkku O, Kuoppamäki M, Syvälahti E, Hietala J.

Psychopharmacology (Berl). 1999 Jul;145(1):76-81.

PMID:
10445375
40.

Association between the functional variant of the catechol-O-methyltransferase (COMT) gene and type 1 alcoholism.

Tiihonen J, Hallikainen T, Lachman H, Saito T, Volavka J, Kauhanen J, Salonen JT, Ryynänen OP, Koulu M, Karvonen MK, Pohjalainen T, Syvälahti E, Hietala J.

Mol Psychiatry. 1999 May;4(3):286-9.

41.

Measurement of striatal D2 dopamine receptor density and affinity with [11C]-raclopride in vivo: a test-retest analysis.

Hietala J, Någren K, Lehikoinen P, Ruotsalainen U, Syvälahti E.

J Cereb Blood Flow Metab. 1999 Feb;19(2):210-7.

PMID:
10027776
42.

Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia.

Hietala J, Syvälahti E, Vilkman H, Vuorio K, Räkköläinen V, Bergman J, Haaparanta M, Solin O, Kuoppamäki M, Eronen E, Ruotsalainen U, Salokangas RK.

Schizophr Res. 1999 Jan 4;35(1):41-50.

PMID:
9988840
43.

The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers.

Pohjalainen T, Rinne JO, Någren K, Lehikoinen P, Anttila K, Syvälahti EK, Hietala J.

Mol Psychiatry. 1998 May;3(3):256-60.

44.

Sex differences in the striatal dopamine D2 receptor binding characteristics in vivo.

Pohjalainen T, Rinne JO, Någren K, Syvälahti E, Hietala J.

Am J Psychiatry. 1998 Jun;155(6):768-73.

PMID:
9619148
45.

Striatal presynaptic dopamine function in type 1 alcoholics measured with positron emission tomography.

Tiihonen J, Vilkman H, Räsänen P, Ryynänen OP, Hakko H, Bergman J, Hämäläinen T, Laakso A, Haaparanta-Solin M, Solin O, Kuoppamäki M, Syvälahti E, Hietala J.

Mol Psychiatry. 1998 Mar;3(2):156-61.

46.

Smoking and cognitive deficits in schizophrenia: a pilot study.

Taiminen TJ, Salokangas RK, Saarijärvi S, Niemi H, Lehto H, Ahola V, Syvälahti E.

Addict Behav. 1998 Mar-Apr;23(2):263-6.

PMID:
9573430
47.

Deramciclane, a putative anxiolytic drug, is a serotonin 5-HT2C receptor inverse agonist but fails to induce 5-HT2C receptor down-regulation.

Pälvimäki EP, Majasuo H, Kuoppamäki M, Männistö PT, Syvälahti E, Hietala J.

Psychopharmacology (Berl). 1998 Mar;136(2):99-104.

PMID:
9551765
48.

Is positive placebo response in chronic schizophrenia investigator-dependent?

Taiminen T, Syvälahti E, Saarijärvi S, Niemi H, Lehto H, Ahola V, Salokangas RK.

J Nerv Ment Dis. 1997 Oct;185(10):644-5. No abstract available.

PMID:
9345257
49.

Effects of lorazepam administration on striatal dopamine D2 receptor binding characteristics in man--a positron emission tomography study.

Hietala J, Kuoppamäki M, Någren K, Lehikoinen P, Syvälahti E.

Psychopharmacology (Berl). 1997 Aug;132(4):361-5.

PMID:
9298513
50.

Allelic association between D2 but not D1 dopamine receptor gene and alcoholism in Finland.

Hietala J, Pohjalainen T, Heikkilä-Kallio U, West C, Salaspuro M, Syvälahti E.

Psychiatr Genet. 1997 Spring;7(1):19-25.

PMID:
9264134

Supplemental Content

Loading ...
Support Center